Search Results - "Vergo, M. T."

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates by Kelley, R.K., Nimeiri, H.S., Munster, P.N., Vergo, M.T., Huang, Y., Li, C.-M., Hwang, J., Mulcahy, M.F., Yeh, B.M., Kuhn, P., Luttgen, M.S., Grabowsky, J.A., Stucky-Marshall, L., Korn, W.M., Ko, A.H., Bergsland, E.K., Benson, A.B., Venook, A.P.

“…Based upon preclinical evidence for improved antitumor activity in combination, this phase I study investigated the maximum-tolerated dose (MTD), safety,…”
Get full text

A phase I trial of the combination of temsirolimus (TEM) and sorafenib (SOR) in advanced hepatocellular carcinoma (HCC) by Kelley, R. K., Nimeiri, H. S., Vergo, M. T., Bergsland, E. K., Ko, A. H., Munster, P. N., Reinert, A., Mulcahy, M. F., Benson, A. B., Venook, A. P.

“…Abstract only…”
Get full text

5′-Peptidyl substituents allow a tuning of the affinity of oligodeoxyribonucleotides for RNA by Sarracino, David A., Steinberg, Joshua A., Vergo, Maxwell T., Woodworth, Graeme F., Tetzlaff, Charles N., Richert, Clemens

“…The affinity of amide-linked 5′-aminoacyl and 5′-dipeptidyl DNA octamers for two RNA undecamers with 3′-overhangs was measured via UV melting analysis. A…”
Get full text

Phase I trial of temsirolimus (TEM) plus sorafenib (SOR) in advanced hepatocellular carcinoma (HCC) by Kelley, R. K., Nimeiri, H. S., Vergo, M. T., Chia, K., Mulcahy, M. F., Bergsland, E. K., Ko, A. H., Munster, P. N., Benson, A. B., Venook, A. P.

“…Abstract only 296 Background: SOR prolongs survival in patients (pts) with HCC. In preclinical studies, mammalian target of rapamycin (mTOR) inhibitors (I)…”
Get full text

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates by Kelley, R K, Nimeiri, H S, Munster, P N, Vergo, M T, Huang, Y, Li, C-M, Hwang, J, Mulcahy, M F, Yeh, B M, Kuhn, P, Luttgen, M S, Grabowsky, J A, Stucky-Marshall, L, Korn, W M, Ko, A H, Bergsland, E K, Benson, 3rd, A B, Venook, A P

“…Based upon preclinical evidence for improved antitumor activity in combination, this phase I study investigated the maximum-tolerated dose (MTD), safety,…”
Get full text

Prevalence of Sudden Death in Palliative Care: Data from the Australian Palliative Care Outcomes Collaborative (PCOC) by Ekström, Magnus, MD, PhD, Vergo, Maxwell T., MD, Ahmadi, Zainab, MD, Currow, David C., B Med, MPH, PhD, FRACP, FAHMS

“…Abstract Context Advanced, life-limiting illnesses are likely to have a predictable functional decline through a terminal phase to death, but some patients may…”
Get full text

Sudden Death in Palliative Care by Currow, David C., BMed, MPH, PhD, FRACP, Vergo, Maxwell T., MD, Ekstrom, Magnus, MD, PhD

Get full text